OncoMatch/Clinical Trials/NCT07250542
A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer
Is NCT07250542 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Fasudil hydrochloride combined with immunotherapy for prostate cancer.
Treatment: Fasudil hydrochloride combined with immunotherapy — Carrying out clinical trials of salbutamol hydrochloride combined with immunotherapy and castration for the treatment of prostate cancer is of great significance. Firstly, it can verify the efficacy and safety of this combination in the treatment of prostate cancer, providing a scientific basis for its clinical application. Secondly, through clinical trials, the mechanism of action of salbutamol hydrochloride combined with immunotherapy can be further studied. Finally, this clinical trial can further expand the treatment strategies for prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Demographics
Prior therapy
Must have received: chemotherapy (docetaxel)
failed at least one chemotherapy regimen containing docetaxel
Must have received: novel endocrine therapy
failed at least one standard novel endocrine therapy
Lab requirements
Kidney function
Serum creatinine < 1.5 mg/dl or creatinine clearance rate ≥ 60 cc/min
Liver function
Total bilirubin < 1.5x ULN, ALT/AST < 2x ULN
Abnormal liver function: Total bilirubin in blood is less than 1.5 times the upper limit of normal value, and the ratio of blood ALT to AST is less than 2 times the upper limit of normal value; Abnormal kidney function: Serum creatinine is less than 1.5 mg/dl or the creatinine clearance rate is greater than or equal to 60 cc/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07250542 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received chemotherapy and novel endocrine therapy.
Is there an age limit?
Yes. Patients must be 85 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages